|
Characterizing differential efficacy and phenotypic response to proteasome and survivin inhibitors in colorectal cancers using a high throughput organoid assay. |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Employment - CerFlux, Inc. |
Research Funding - CerFlux, Inc. |
|
|
Employment - CerFlux, Inc. |
Research Funding - CerFlux, Inc. |
|
|
No Relationships to Disclose |
|
Mary Kathryn Sewell-Loftin |
Employment - Cerflux, Inc. |
Consulting or Advisory Role - Cerflux, Inc. |
Research Funding - Cerflux, Inc. |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Employment - CerFlux, Inc. |
Leadership - CerFlux, Inc. |
Stock and Other Ownership Interests - CerFlux, Inc. |
Research Funding - CerFlux, Inc. |
Patents, Royalties, Other Intellectual Property - 3 US, 1 EU, 1 UK patents issued. 6 additional patents pending. Broadly related to microfluidics, bioengineering, lab-chip, tissue, or tumor models. |
Other Relationship - American Cancer Society; BIO Alabama; Breast Cancer Research Foundation of Alabama; O'Neal Comprehensive Cancer Center |